Skip to content

Regeneron Pharmaceuticals

US · REGN #285 by market cap Listed 1970
920.69 -1.71 -0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 935.34 +1.40%
After-hours 920.69 0.00%
Overnight 925.57 +0.34%
973.36599.96920.692026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on REGN?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +18.4% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 2.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days B → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 6 of 6 factors. Missing data is not a zero score.

Overall B+
ValuationGrowthProfitMomentumHealthAnalyst
Valuation C

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 20.4x Better than 42%
Forward P/E 12.9x Better than 64%
Price / Sales 5.8x Better than 19%
P/E vs own 5-yr range 74th pctl Better than 33%
Growth C+

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 5.6% Better than 49%
Net income CAGR (3Y) 1.3% Better than 43%
Free cash flow CAGR (3Y) 3.5% Better than 43%
Profitability A

How much profit the business keeps from each dollar of sales and capital.

Gross margin 85.4% Better than 94%
Operating margin 25.8% Better than 85%
Net margin 31.4% Better than 91%
Return on equity 14.9% Better than 68%
Return on invested capital 11.9% Better than 75%
Momentum A

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 10.4% Better than 90%
6-month return 44.3% Better than 94%
12-month return (ex latest month) 8.8% Better than 44%
Distance below 52-week high 7.1% Better than 91%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 4.1x Better than 82%
Debt to assets 6.7% Better than 76%
Interest coverage 120.4x Better than 94%
Free cash flow / net income 83.6% Better than 28%
Analyst View C-

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 69.6% Better than 48%
Upside to average target 5.0% Better than 8%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -3.64%
1M +14.02%
3M +11.38%
6M +41.86%
YTD +19.74%
1Y +25.41%
3Y +15.93%
5Y +42.39%

Key statistics

Price & volume

Prev close
922.40
Open
935.80
Day range
916.66 - 948.42
Avg price
926.22
Volume
878.26K
Turnover
813.46M
Amplitude
3.44%
52-week range
590.23 - 990.72

Valuation

P/E
22.20
P/E (TTM)
20.35
P/B
2.84
EPS
41.48
Net profit
4.29B
Net assets
33.50B

Share structure

Market cap
95.24B
Float cap
91.57B
Shares out
103.45M
Float shares
99.46M

Dividend & listing

Dividend (TTM)
3.70
Listing date
1970-01-01
52-week range 83% of range
590.23 990.72

7.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-20.63M net over the window

Short interest

Shares short
2.22M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Regeneron Pharmaceuticals (REGN)?

Regeneron Pharmaceuticals last traded at 920.69. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Regeneron Pharmaceuticals's market cap?

About 95.24B.

What is the P/E ratio of Regeneron Pharmaceuticals?

The trailing twelve-month P/E is 20.35, above its own 5-year average of 18.34 — toward the top of its historical range (73.94% percentile). See the Valuation tab for the full history.

Does Regeneron Pharmaceuticals pay a dividend?

Yes. The trailing dividend yield is 0.40%. See the Dividends tab for the full payment history.

Is Regeneron Pharmaceuticals a buy according to analysts?

The consensus of 23 analysts is a Buy rating, with an average 12-month price target of 959.57, which implies 4.2% upside from the current price. This is not investment advice.

What is Regeneron Pharmaceuticals's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Regeneron Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.

Regeneron Pharmaceuticals discussion 0 comments

Add a comment